Oncuria® Test Covid-19 RT-PCR Test DiaCarta’s ColoScapeTM & FIT Tests
RadToxTM cfDNA Radiation Response Test
SARS-CoV-2 RT-PCR Test
- Highly Accurate
100% clinical sensitivity and 100% specificity - FDA EUA Authorized: CE-IVD
- 24-48 hours Result Turn-Around Time
- Sample type: Nasopharyngeal Swab
Method of sample collection:
- Nasopharyngeal (NP)
ColoScapeTM Colorectal Cancer Mutation Detection Test
- Detects 61 mutations in 8 genes and 7 methylation markers associated with Colorectal Cancer.
- Uses novel XNA technology that provides high level of sensitivity and specificity for precancerous lesions.
- Convenient sample collection with blood.
- Fast turnaround time to get results.
- ColoScape has clinical sensitivity of 92.2% and specificity of 100% for CRC
- ColoScape 95% specificity and 62.5 % sensitivity for precancerous lesions or advanced adenomas https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244332
To find out if you are at risk, we offer the following tests : FIT (fecal immunochemical test) and ColoScapeTM
Please note that a physician prescription is needed to order this test*
RadToxTM cfDNA Radiation Response Test
- The RadToxTM Test is a molecular assay for early assessment of patient response to radiotherapy and chemotherapy by monitoring changes in cell-free circulating DNA (cfDNA) levels
- RadToxTM test is a direct cfDNA quantitation method based on SuperbDNATM technology.
- Plasma cell-free DNA (cfDNA) concentration correlates with radiation doses and predicts the level of radiation damage to tumor cells.
- The Cancer rates are predicted to increase from 9 million in 2017 to 26 million by 2030.
- Almost 30-50% of individuals having cancer receive radiation therapy alone or in combination with surgery and chemotherapy. Almost 7 million patients receive radiation treatment per year.
- RadToxTM fulfills an unmet medical need in cancer radiation therapy by enabling early and rapid assessment of patient’s response to treatment.
- The assay would allow dose escalation to tumors in less sensitive patients, aid the development of radiotoxicity mitigators, and reduce the over-treatment risk for sensitive patients
Please note that a physician prescription is needed to order this test*
QuantiDNATM Direct cfDNA Test
a cell-free DNA (cfDNA) quantification test
The QuantiDNATM DNA Measurement Assay is a cell-free DNA (cfDNA) quantification method. The assay uses direct cfDNA quantification without DNA extraction or qPCR to quantify human cfDNA from plasma. The method uses DNA-hybridization-based, modified branched DNA (bDNA) technology. The target DNA is captured through DNA hybridization and the signals associated with the quantity of the target DNA, rather than the target by itself, are amplified and quantified by a luminometer.
Oncuria® Multiplex Immunoassay for Bladder Cancer
Oncuria® is the first-of-its-kind multiplex protein-based immunoassay to provide early
detection, therapy choice, and disease monitoring of bladder cancer. This 10-biomarker test has been developed for the early detection of bladder cancer in patients presenting with hematuria or with a history of bladder cancer on disease surveillance. The immunoassay is performed using Luminex ® xMAP technology. The physical components of multiplex assay, a library of detection and capture antibodies, and the secondary reagents have undergone extensive optimization for consistent implementation. Analytical validation of the test has assessed selectivity, sensitivity, specificity, accuracy, linearity, dynamic range, and detection threshold, using voided urine as the test matrix.
Why choose DiaCarta?
Novel XNA technology provides high level of sensitivity
FDA EUA COVID 19 RTPCR reagents
ColoScape Colorectal Cancer Test highly sensitive to precancerous lesions
Personalize radiation therapy to lower adverse events and damage to organs
HPV test for head and neck cancer
